WuXi Biologics (Cayman) Balance Sheet Health
Financial Health criteria checks 6/6
WuXi Biologics (Cayman) has a total shareholder equity of CN¥45.5B and total debt of CN¥2.6B, which brings its debt-to-equity ratio to 5.8%. Its total assets and total liabilities are CN¥57.0B and CN¥11.5B respectively. WuXi Biologics (Cayman)'s EBIT is CN¥4.6B making its interest coverage ratio -23.6. It has cash and short-term investments of CN¥10.7B.
Key information
5.80%
Debt to equity ratio
CN¥2.64b
Debt
| Interest coverage ratio | -23.6x |
| Cash | CN¥10.71b |
| Equity | CN¥45.48b |
| Total liabilities | CN¥11.50b |
| Total assets | CN¥56.98b |
Recent financial health updates
WuXi Biologics (Cayman) (HKG:2269) Seems To Use Debt Quite Sensibly
May 07
Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?
Dec 17WuXi Biologics (Cayman) (HKG:2269) Has A Pretty Healthy Balance Sheet
Sep 12Recent updates
WuXi Biologics (Cayman) Inc.'s (HKG:2269) 27% Jump Shows Its Popularity With Investors
May 08WuXi Biologics (Cayman) (HKG:2269) Seems To Use Debt Quite Sensibly
May 07WuXi Biologics (Cayman) Inc. (HKG:2269) Stocks Shoot Up 28% But Its P/E Still Looks Reasonable
Mar 16
Follow The Molecule Strategy And Global Expansion Will Secure Future Opportunities
Feb 09 Robust pipeline growth with new projects and North American focus drive future revenue and stabilize amidst geopolitical tensions.WuXi Biologics (Cayman) Inc.'s (HKG:2269) P/E Is On The Mark
Jan 25Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?
Dec 17After Leaping 29% WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Are Not Flying Under The Radar
Sep 26WuXi Biologics (Cayman) (HKG:2269) Has A Pretty Healthy Balance Sheet
Sep 12Shareholders May Not Be So Generous With WuXi Biologics (Cayman) Inc.'s (HKG:2269) CEO Compensation And Here's Why
Jun 12Some Confidence Is Lacking In WuXi Biologics (Cayman) Inc. (HKG:2269) As Shares Slide 25%
Jun 11Some WuXi Biologics (Cayman) Inc. (HKG:2269) Shareholders Look For Exit As Shares Take 25% Pounding
Jun 11Financial Position Analysis
Short Term Liabilities: 2269's short term assets (CN¥23.6B) exceed its short term liabilities (CN¥8.6B).
Long Term Liabilities: 2269's short term assets (CN¥23.6B) exceed its long term liabilities (CN¥2.9B).
Debt to Equity History and Analysis
Debt Level: 2269 has more cash than its total debt.
Reducing Debt: 2269's debt to equity ratio has reduced from 14.7% to 5.8% over the past 5 years.
Debt Coverage: 2269's debt is well covered by operating cash flow (197.9%).
Interest Coverage: 2269 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/13 05:53 |
| End of Day Share Price | 2025/05/13 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
WuXi Biologics (Cayman) Inc. is covered by 47 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bo Li | BofA Global Research |
| Shun Kei Law | CCB International Securities Limited |
| Jian Xiong Lim | CFRA Equity Research |